| Toggle Summary
|
Anthera Pharmaceuticals Launches With A Proven Leadership Team And Significant Series A Funding
– CEO Follows Up Success at Peninsula Pharmaceuticals by Taking on New Therapeutic Area –
|
View HTML
|
| Toggle Summary
|
Anthera Pharmaceuticals Appoints David E. Thompson To Board Of Directors
|
View HTML
|
| Toggle Summary
|
Anthera Licenses Portfolio of Anti-Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd.
|
View HTML
|
| Toggle Summary
|
Anthera Pharmaceuticals Secures $36M Venture Financing To Initiate Clinical Programs
|
View HTML
|
| Toggle Summary
|
Anthera Employee Keiko Mitsunobu Finishes Honolulu Marathon In Successful Effort To Raise Money For Children's Hospital Oakland Research Institute
|
View HTML
|
| Toggle Summary
|
Anthera Receives FDA Approval to begin phase 2 "PLASMA" trial with A-002 For patients with coronary atherosclerosis
|
View HTML
|
| Toggle Summary
|
Anthera Receives IND Approval from FDA to begin phase 2 "IMPACTS" trial with A-001 for prevention of acute chest syndrome in patients with sickle cell disease
|
View HTML
|
| Toggle Summary
|
Dr. David D. Waters Joins Anthera Pharmaceuticals As Cardiovascular Research Fellow
|
View HTML
|
| Toggle Summary
|
Anthera pharmaceuticals' Inc. announces formation of clinical advisory board for cardiovascular program
|
View HTML
|
| Toggle Summary
|
Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
|
View HTML
|
